We are live on ! Find out more
RPRX

Repros Therapeutics Inc.
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

77 hedge funds and large institutions have $379M invested in Repros Therapeutics Inc. in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more capital invested

Capital invested by funds: $379M → $379M (+$60.9K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less funds holding

Funds holding: 8077 (-3)

14% less call options, than puts

Call options by funds: $9.62M | Put options by funds: $11.2M

24% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 29

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

Holders
77
Holders Change
-3
Holders Change %
-3.75%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
22
Reduced
29
Closed
12
Calls
$9.62M
Puts
$11.2M
Net Calls
-$1.56M
Net Calls Change
+$543K

RPRX Hedge Fund Activity: Q2 2014 in Review

77 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2014, worth a combined $379M — up 0.02% from $379M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of RPRX and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 22 added.

The largest buyer was Sarissa Capital Management, adding an estimated $7.22M. The largest seller was PFM Health Sciences, cutting an estimated $4.3M.

  • 77 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2014, down from 80 in Q1 2014.
  • Funds reported $379M of Repros Therapeutics Inc. stock for Q2 2014, up 0.02% quarter-over-quarter.
  • 9 funds opened new Repros Therapeutics Inc. positions in Q2 2014 and 12 closed out, a net change of -3 holders.
  • The largest Repros Therapeutics Inc. buyer in Q2 2014 was Sarissa Capital Management, an estimated $7.22M added.
  • The largest Repros Therapeutics Inc. seller in Q2 2014 was PFM Health Sciences, an estimated $4.3M sold.

Based on aggregated 13F filings for Q2 2014.